New drugs targeting Alzheimer's disease
Novel brain-penetrant drugs for translation-targeting therapeutics of Alzheimer’s disease
This study is exploring a new drug that could help treat Alzheimer's disease by targeting a specific enzyme in the brain, with the hope of improving memory and thinking skills in people affected by this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Transchromix, LLC. NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10821732 on NIH RePORTER |
What this research studies
This research focuses on developing innovative drugs that can penetrate the brain to treat Alzheimer's disease, a condition that leads to memory loss and cognitive decline. The approach involves understanding the role of a specific enzyme, G9a, in the disease's progression and using a drug called MS1262 to inhibit its activity. By doing so, the researchers aim to reverse harmful changes in brain proteins associated with cognitive functions and restore normal behavior in animal models. The project is a collaboration between TransChromix, LLC and the UNC School of Medicine.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those in mid to late stages of the condition.
Not a fit: Patients with early-stage Alzheimer's or other forms of dementia unrelated to Alzheimer's may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options that significantly improve cognitive and emotional functions in Alzheimer's patients.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting G9a in Alzheimer's models, indicating potential for success.
Where this research is happening
Chapel Hill, United States
- Transchromix, LLC. — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Chen, Xian — Transchromix, LLC.
- Study coordinator: Chen, Xian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.